SAB Biotherapeutics, Inc.·4

Nov 30, 5:00 PM ET

King Michael 4

4 · SAB Biotherapeutics, Inc. · Filed Nov 30, 2023

Insider Transaction Report

Form 4
Period: 2023-11-30
King Michael
CHIEF FINANCIAL OFFICER
Transactions
  • Purchase

    Common Stock

    2023-11-30$0.90/sh+5,000$4,5005,000 total
Footnotes (1)
  • [F1]Represents 5,000 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4